
    
      The study was conducted as a single-dose, randomized, 2-period sequence crossover study under
      fasting condition comparing equal dose of test and reference products with an interval period
      of at least 7 days. The period of confinement was at least 10 hours before dosing until after
      24 hours blood collection in each period. Subjects were asked to return to the clinic for
      subsequent blood circulation Twenty-six subjects (26) were recruited for the study of which
      twenty-three (23) completed the clinical portion of the study. Subject #17 was withdrawn by
      sponsor's representative due to adverse event unrelated to the drug), subject #18 and subject
      #25 voluntarily withdrew due to adverse event
    
  